Where Is The Immunoassay Interference Blocker Market Heading With Global?

Posted by Merin John on May 21st, 2021

The rapidly increasing prevalence of chronic diseases and the growth of the aging population across the world are among factors that are expected to increase the need for biochemical testing for the management of chronic diseases. The global increase in aging population is expected to increase the demand for diagnostic kits and reagents for the detection of age-related as well as other chronic conditions, which is expected to boost the immunoassay interference blocker market.

According to latest research by PMR, the global immunoassay interference blocker market is estimated to have accounted for ~ US$ 200.0 Mn in terms of value in 2018. The report on the immunoassay interference blocker market further projects that the immunoassay interference blocker market is likely to expand at a CAGR of ~ 7% during the period 2019-2029.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/24343

Company Profiles:

Abcam plc

AMS Biotechnology (Europe) Limited

Aviva Systems Biology Corporation

Bio-Rad Laboratories, Inc.

Meridian Bioscience, Inc.

Roche Diagnostics GmbH

Rockland Immunochemicals, Inc.

Scantibodies Laboratory, Inc.

Thermo Fisher Scientific

Highly Dynamic Competition in the Global Landscape

The immunoassay interference blocker market is expanding in tandem with the growth of technology. Companies are channelizing efforts to maximize productivity, flexibility, and throughput capabilities, as well as redefine the productivity of their staff.

Increase in product consolidation activities, which include sales and service agreements, collaborations, rising research & development activities, new product launches, joint ventures, partnerships, patent transfers, and mergers & acquisitions among global and regional players, are among the characteristics of the overall competition in the global immunoassay interference blocker market.

The number of organizations involved in the immunoassay interference blocker market has increased during the past few years. The market of immunoassay interference blockers has been based on established NAT technologies and immunoassays. Although the NAT market continues to be managed by Roche, Thermo Fisher Scientific, and Bio-Rad Laboratories, Inc., many other biotechnology corporations have recently acquired significant IP property in this area.

The antibody interference blockers segment is a prominent revenue segment by product type in the immunoassay interference blocker market, which accounted for a revenue share of ~ 55.0% 2018. The antibody interference blockers segment is followed by the detection interference blockers that also generated significant revenue in the immunoassay interference blocker market.